Study Links Gabapentinoids to Increased Risk of Severe COPD Exacerbation
A recent study involving over 10,000 individuals has discovered a link between gabapentinoids, a class of drugs used to treat seizures and neuropathic pain, and an increased risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD). The research was carried out by experts from McGill University and the Lady Davis Institute for Medical Research, who analysed Canadian insurance data.
Table of Contents
Gabapentinoids and COPD Risk
The study highlighted that the highest risk of severe COPD exacerbation was associated with approximately six months of continuous gabapentinoid use. This discovery supports prior warnings issued by regulatory agencies, including the US Food and Drug Administration (FDA), which cautioned in December 2019 that severe breathing difficulties might occur in patients using gabapentinoids.
An Eye-Opening Analysis of Insurance Data
The study population comprised 13,504 patients who initiated gabapentinoid treatment. By analyzing the data, researchers found that gabapentinoid use was linked to an increased risk of severe COPD exacerbation, especially in patients with epilepsy, neuropathic pain, and other chronic pain conditions.
Implications for Health Practitioners and Patients
The findings of this study have significant implications for both health practitioners and patients. It underscores the need for caution in prescribing and using these medications, particularly among patients with COPD. The study also highlights the potential risks associated with the widespread prescription of gabapentinoids for various types of pain, a practice that diverges from their approved indications.
The findings were published in the Annals of Internal Medicine, adding to the growing body of evidence regarding the potential risks of gabapentinoid use in people with COPD, a group that already may experience compromised respiratory function.
